Classes of ITD predict outcomes in patients with AML treated with FLT3 inhibitors
G. W. Schwartz, B. Manning, Y. Zhou, P. Velu, A. Bigdeli, R. Astles, A. Lehman, J. Morrissette, A. Perl, M. Carroll, R. Faryabi
The paper classifies FLT3-ITD mutations into typical and atypical based on nucleotide composition and shows typical ITD carriers have better outcomes with FLT3 inhibitors.
bioRxiv · May 14, 2018Cancer Biology